Express Pharma
FEBRUARY 21, 2024
billion by 2029. “ billion by 2029. “ billion in 2023, and GlobalData projects it to surpass $14 billion by 2029. The ADC contains an anti-TROP2 monoclonal antibody covalently linked to the topoisomerase I inhibitor cytotoxic payload. GlobalData estimates the drug to earn $3.12 GlobalData estimates the drug to earn $3.12
Express Pharma
SEPTEMBER 19, 2023
Venus Remedies has secured marketing authorisation from Serbia for gemcitabine and docetaxel, widely used chemotherapy drugs. billion by 2029 at a compounded annual growth rate (CAGR) of 8.2 With this, the company has secured 511 marketing approvals for its oncology products across 66 countrles. per cent from 2021 to 2030.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
FEBRUARY 21, 2024
TAGRISSO as a combination treatment with chemotherapy was recently approved in the US, based on data from the FLAURA2 Phase III trial. Research predicts 2029 small molecule oncology market leaders The post EGFR inhibitor could provide major advance in lung cancer appeared first on European Pharmaceutical Review.
European Pharmaceutical Review
MAY 20, 2024
This includes antibody production, chemotherapy drug and linker synthesis, conjugating the drug-linker to the antibody, as well as filling of the completed ADC substance, AstraZeneca confirmed. It is anticipated that operations will be ready to commence from 2029.
Express Pharma
JUNE 13, 2024
per cent from 19,871 in 2023 to 25,777 in 2029. Currently, chemotherapy remains the mainstay of treatment across the first and second line for advanced pancreatic cancer.
European Pharmaceutical Review
OCTOBER 26, 2023
Yet as the market continues to recognise the value of these treatments, especially with them having “clear benefits over current monotherapy and combination therapy options in cancer treatment”, it is unsurprising that GlobalData’s research predicted the ADC oncology therapy market will value more than $36 billion by 2029.
Pharmaceutical Technology
MAY 12, 2023
The agent is a human epidermal growth factor receptor 2 (HER2)-targeting ADC that utilises Eisai’s chemotherapy Halaven (eribulin) as its payload. GlobalData analyst consensus forecasts project sales to reach $11.5bn by 2029, a 29% compound annual growth rate (CAGR). targeting ADC.
Expert insights. Personalized for you.
111 
Let's personalize your content